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BACKGROUND: Poly(ADP-ribose) polymerase 1 (PARP1), γH2AX, BRCA1, and BRCA2 are conventional molecular
indicators of DNA damage in cells and are often overexpressed in various cancers. In this study, we aimed, using
immunohistochemical detection, whether the co-expression of PARP1, γH2AX, BRCA1, and BRCA2 in breast
carcinoma (BCA) tissue can provide more reliable prediction of survival of BCA patients. MATERIALS AND
METHODS: We investigated immunohistochemical expression and prognostic significance of the expression ofHealth, Welfare and Family Affairs. All samples derived from the National Biobank of
Korea were obtained with informed consent under Institutional Review Board–
approved protocols.
Received 17 February 2015; Revised 18 April 2015; Accepted 24 April 2015
© 2015 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1936-5233/15
http://dx.doi.org/10.1016/j.tranon.2015.04.004
240 PARP1, γH2AX, BRCA1, and BRCA2 in breast carcinoma Park et al. Translational Oncology Vol. 8, No. 4, 2015PARP1, γH2AX, BRCA1, and BRCA2 in 192 cases of BCAs. RESULTS: The expression of these four molecules
predicted earlier distant metastatic relapse, shorter overall survival (OS), and relapse-free survival (RFS) by
univariate analysis. Multivariate analysis revealed the expression of PARP1, γH2AX, and BRCA2 as independent
poor prognostic indicators of OS and RFS. In addition, the combined expressional pattern of BRCA1,
BRCA2, PARP1, and γH2AX (CSbbph) was an additional independent prognostic predictor for OS (P b .001) and
RFS (P b .001). The 10-year OS rate was 95% in the CSbbph-low (CSbbph scores 0 and 1) subgroup, but that was
only 35% in the CSbbph-high (CSbbph score 4) subgroup. CONCLUSION: This study has demonstrated that the
individual and combined expression patterns of PARP1, γH2AX, BRCA1, and BRCA2 could be helpful in
determining an accurate prognosis for BCA patients and for the selection of BCA patients who could potentially
benefit from anti-PARP1 therapy with a combination of genotoxic chemotherapeutic agents.
Translational Oncology (2015) 8, 239–249Introduction
Poly(ADP-ribose) polymerase 1 (PARP1) is important in the repair of
DNA damage as it immediately binds to DNA breaks to induce
recruitment and activation of other DNA repair proteins [1,2].
However, the major role of PARP1 in the repair of DNA single-stand
breaks could induce progression of human malignant tumors [3]. The
aberrant DNA repairing activity from the overexpression of PARP1 in
tumor cells could enhance the anti-apoptotic property of tumor cells,
which results in chemotherapy-resistant cancers [3]. Therefore, it is
suggested that PARP1 could affect tumor development, and the
overexpression of PARP1 is associated with advanced clinical
characteristics and poor survival of human malignant tumors,
including breast carcinoma (BCA) [4,5], ovarian carcinoma [6],
melanoma [7], and glioblastoma [8]. Thus, the antitumoral effect of
PARP1 inhibition by small interfering RNA or chemicals has been
evaluated, and PARP1 inhibition increased apoptosis of cancer cells
when used in conjunction with a DNA damaging therapy [9–11]. In
addition, several PARP inhibitors have been developed and are in
clinical trials in combination with chemotherapeutic drugs [3,12,13].
γH2AX is the phosphorylated form (serine 139) of the H2AX
protein and is important in the repair of DNA double-strand breaks
(DSBs) [14–16]. Phosphorylation of H2AX causes a conformational
change in the DNA-H2AX complex, which allows room for the
recruitment of proteins needed to repair DSBs [17–20]. Therefore,
γH2AX levels could increase in conjunction with increases in
cancer-associated genomic instability [14]. Consequently, as the
expression of PARP1 increases in advanced cancers, increased
γH2AX levels may reflect the progression of human cancer. In
triple-negative BCA [21] and endometrial cancer [22,23], the
expression of γH2AX is associated with poor survival of cancer
patients. However, other DNA damage response (DDR) molecules,
especially BRCA1/2, are necessary for the repair of DSB. Therefore, if
there is no γH2AX-BRCA1/2–related repair for DSB, PARP1
inhibitors eventually induce unrepairable DSB. Thus, PARP1
inhibitors could selectively target cancer cells with defects or loss of
BRCA1/2[3,24]. Recent reports have shown that PARP inhibitors
are effective for the treatment of BRCA-deficient BCA [13,25], but
they have had limited success with cancers not associated with
BRCA1/2[1,26]. However, the PARP inhibitor, olaparib, was
effective in both ovarian carcinomas with a BRCA1/2 mutation and
without a BRCA1/2 mutation [27].When considering the relationships between the expression of
PARP1, the phosphorylation of H2AX, and the induction of
BRCA1/2, there is a possibility that these molecules are cooperatively
involved in the progression of cancer through their roles in the
resistance to DNA damaging agents. Moreover, recent reports have
shown that evaluation of the expression of these molecules by
immunohistochemistry is helpful for the evaluation of the effect of
the expression of these molecules [5,21,28]. However, there are no
reports that strategically evaluated the expression of these molecules in
breast cancer. Therefore, this study investigated the immunohisto-
chemical expression of PARP1, γH2AX, BRCA1, and BRCA2 and
evaluated the combined expression of these molecules in the
prognosis of BCAs.
Materials and Methods
Patients and Tissue Samples
The BCAs diagnosed between January 1997 and December 2003
in Chonbuk National University Hospital were subjected to this
study. Thereafter, 192 cases with original histologic slides, paraffi-
n-embedded tissue blocks, and clinical information available were
included in the present study. This study was approved by the
Institutional Review Board of Chonbuk National University
Hospital. Informed consent was provided according to the
Declaration of Helsinki.
The age of the 192 BCA patients ranged from 22 to 73 years
(mean, 47 years). The type of operation in 112 patients was modified
radical mastectomy, and 80 patients received breast conserving
surgery. Postoperatively, 169 patients received systemic chemother-
apy (cyclophosphamide, methotrexate, and 5-fluorouracil chemo-
therapy or anthracycline- and taxane-based chemotherapy), and 166
patients received endocrine therapy. One hundred forty-six patients
received both adjuvant chemotherapy and endocrine therapy, and
three patients received no adjuvant therapy. The median duration of
follow-up was 134.8 months (range, 7.7-198.6). Among the 192
BCA patients, 59 patients experienced relapse and 55 patients died
from BCA at the follow-up endpoint. The overall survival (OS) rates
at 5 and 10 years were 82% and 75%, respectively. The histologic
findings were reviewed and classified according to the World Health
Organization Classification [29] by two pathologists (K.Y.J. and
S.J.N.). The stage of the BCA was assigned according to the seventh
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system [30].
Immunohistochemical Staining and Scoring
Immunohistochemical expression of PARP1, γH2AX, BRCA1,
and BRCA2 was evaluated by established tissue microarray (TMA).
The TMAs were arrayed from the original paraffin-embedded tissue
blocks at the most representative area composed mainly of tumor cells
and have the highest tumor grade. Two 3.0-mm tumor cores were
arrayed per case. For the antigen retrieval, the TMA sections were
boiled with Dako Target Retrieval Solution (pH 6.0; Dako, Glostrup,
Denmark) using a microwave oven for 20 minutes. Thereafter, the
TMA sections were incubated with anti-PARP1 (1:100; Santa Cruz
Biotechnology, Santa Cruz, CA), anti-γH2AX (Ser 139; 1:100; Cell
Signaling Technology, Beverly, MA), anti-BRCA1 (1:100; Abcam,
Cambridge, MA), and anti-BRCA2 (1:100; Abcam) antibodies. The
scoring for the immunohistochemical staining was performed by two
pathologists (K.Y.J. and K.M.K.) by consensus under a multiviewing
microscope without knowledge of the clinicopathologic information.
Immunohistochemical staining for PARP1, BRCA1, and BRCA2 was
evaluated by the sum of the staining intensity scores (0, no staining; 1,
weak staining; 2, intermediate staining; and 3, strong staining) and
the staining area scores (0, no staining cells; 1, 1% of the cells stained
positive; 2, 2-10% of the cells stained positive; 3, 11-33% of the cells
stained positive; 4, 34-66% of the cells stained positive; and 5,
67-100% of the cells stained positive) in each TMA core [31–33].
Thereafter, the scores of two TMA cores from the same case were
added and used for the analysis. The sum score ranged from 0 to 16.
To quantify the number of γH2AX-positive tumor cells, the number
of γH2AX-positive tumor cells was counted in five high-power fields
(HPFs; magnification, ×400) in each TMA core at the highest
γH2AX-positive numbered area. Thereafter, we added the number of
γH2AX-positive tumor cells from the two different TMA cores and
used them for the final analysis [34,35]. The diameter of the HPF was
0.55 mm, and the area of one HPF was 0.238 mm2. Human
epidermal growth factor receptor 2 (HER2) was considered positive
when 10% or more of the tumor cells showed complete and intense
staining at the cell membrane (3+ by American Society of Clinical
Oncology/College of American Pathologists guidelines) [36]. Estro-
gen receptor (ER) and progesterone receptor (PR) were considered
positive when 1% or more of the tumor cells show nuclear expression.
Cell Lines and Western Blot Analysis
MCF7 andMDA-MB-231 cells were purchased from the Korean Cell
Line Bank (KCLB, Seoul, Korea). The cells (5 × 105) were seeded in each
well of a six-well plate and incubated at 37°C in a humidified incubator
containing 5% CO2 overnight. Then, cells were treated with 0.1 μM
camptothecin in DMSO or DMSO as control. After 30 minutes, cells
were harvested for Western blot analysis. The primary antibodies for
PARP1 (Santa Cruz Biotechnology), γH2AX (Ser 139) (Cell Signaling
Technology), BRCA1 (Abcam), BRCA2 (Abcam), and actin (Santa Cruz
Biotechnology) were used in the Western blot analysis.
Statistical Analysis
The BCAs were grouped as positive or negative for the expression
of PARP1, γH2AX, or BRCA1 at the specific cutoff points of the
immunohistochemical staining scores. The cutoff points were
determined by receiver operating characteristic curve analysis at the
highest positive likelihood point for the estimation of death. Therelationships between the clinicopathologic variables included in this
study were determined using Pearson’s chi-square test, and the
P values were adjusted by the Benjamini Hochberg procedure for
multiple comparison. The prognosis of BCA was evaluated by the
analysis of the OS and relapse-free survival (RFS). The endpoint of
follow-up was the date of death of patients or the date of last contact
through June 2013. The duration of the OS was calculated as the
time from the date of diagnosis to date of death from BCA. If the
patients were alive at last contact or died from other causes, they were
treated as censored. RFS duration was measured as the time from the
date of diagnosis to the date of death from BCA, date of relapse, or last
contact. Patients who were alive at last contact with no relapse or who
died from other causes were treated as censored for RFS analysis.
Survival analysis was performed with univariate and multivariate Cox
regression hazard analyses and Kaplan-Meier survival analysis with a
log-rank test using SPSS statistical software (version 19.0; IBM,
Chicago, IL). P values less than .05 were considered to be statistically
significant.
Results
The Expression of PARP1, γH2AX, BRCA1, and BRCA2 and
Their Association With Clinicopathologic Variables
To validate the antibodies used in this study, we performedWestern
blot analysis for BRCA1, BRCA2, PARP1, and γH2AX in two BCA
cell lines treated with camptothecin, one of the conventional DNA
damaging agents. As shown in Figure 1A, these antibodies detected each
protein in the expected position and the expression levels of these
proteins were upregulated by the treatment of camptothecin. In
immunohistochemical staining of BCA tissue, PARP1 and γH2AX are
mainly expressed in the nuclei of the tumor cells (Figure 1B). Although
BRCA1 and BRCA2 are expressed in both the cytoplasm and nuclei of
the tumor cells, we have used nuclear expression in this study [28,37].
The cutoff points for the immunohistochemical staining score for
PARP1, BRCA1, and BRCA2 were 13, 7, and 9, respectively. The
cutoff number of γH2AX-positive tumor cells was 8 (Figure 1C ). The
expression of PARP1, γH2AX, BRCA1, or BRCA2 was grouped
positive in 41% (78/192 of cases), 51% (98/192), 75% (144/192), and
55% (105/192) of BCA, respectively. PARP1 positivity was signifi-
cantly associated with the development of latent distant metastasis,
increased mitotic count, histologic grade, and the expression of BRCA1
and BRCA2. γH2AX positivity was significantly correlated with the
development of latent distant metastasis, increased mitotic count,
histologic grade, and the loss of ER expression or PR expression. There
was an especially strong positive correlation between the expression of
PARP1 and γH2AX (P = .004). The number of γH2AX-positive cells
was significantly higher in the PARP1-positive group compared with
the PARP1-negative group (mean ± standard error, 58 ± 17 vs 26 ± 5,
two-sided t test; P = .039). The expression of both BRCA1 and BRCA2
was significantly correlated with the development of latent distant
metastasis and higher histologic grade (Table 1).
The Expression of PARP1, γH2AX, BRCA1, and BRCA2 Was
Associated With Shorter Survival of BCA Patients by
Univariate Analysis
In 192 BCAs, the factors significantly associated with both OS and
RFS by univariate survival analyses were the age of the patients, tumor
stage, histologic grade, HER2 expression, PR expression, BRCA1
expression (OS, P = .012; RFS, P = .011), BRCA2 expression (OS,
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P b .001), and γH2AX positivity (OS, P b .001; RFS, P b .001;
Figure 1D and Table 2). The patients with tumors expressing PARP1
had a 5.778-fold [95% confidence interval (CI), 3.143-10.623]
greater risk of death (P b .001), and its expression was significantlyassociated with shorter RFS (P b .001; hazard ratio (HR), 3.039; 95%
CI, 1.889-4.888). The expression of γH2AX predicted shorter OS
(P b .001; HR, 4.725; 95% CI, 2.439-9.154) and RFS (P b .001;
HR, 3.706; 95% CI, 2.172-6.325). The expression of BRCA1
predicted shorter OS (P = .012; HR, 2.965; 95% CI, 1.269-6.926)
Table 1. Association of the Expression of PARP1, γH2AX, BRCA1, and BRCA2 with Clinicopathologic Factors
Characteristics No. PARP1 γH2AX BRCA1 BRCA2
Positive PBH Positive PBH Positive PBH Positive PBH
Age, years b50 131 48 (37%) .145 63 (48%) .336 97 (74%) .806 67 (51%) .263
≥50 61 30 (49%) 35 (57%) 47 (77%) 38 (62%)
TNM stage I 35 13 (37%) .581 15 (43%) .625 25 (71%) .894 20 (57%) .821
II 124 49 (40%) 67 (54%) 93 (75%) 65 (52%)
III and IV 33 16 (48%) 16 (48%) 26 (79%) 20 (61%)
T stage 1 55 23 (42%) .145 26 (47%) .761 42 (76%) .957 31 (56%) 1.000
2 122 45 (37%) 63 (52%) 91 (75%) 66 (54%)
3 and 4 15 10 (67%) 9 (60%) 11 (73%) 8 (53%)
LN metastasis Absence 102 36 (35%) .145 51 (50%) .810 72 (71%) .304 53 (52%) .559
Presence 90 42 (47%) 47 (52%) 72 (80%) 52 (58%)
Latent distant metastasis Absence 148 46 (31%) b .001 64 (43%) b .001 103 (70%) .011 69 (47%) b .001
Presence 44 32 (73%) 34 (77%) 41 (93%) 36 (82%)
Histologic type NST 184 76 (41%) .382 93 (51%) .625 137 (74%) .646 99 (54%) .381
Lobular 8 2 (25%) 5 (63%) 7 (88%) 6 (75%)
Tubule formation N75% 33 10 (30%) .256 14 (42%) .052 21 (64%) .375 13 (39%) .162
11-75% 81 31 (38%) 35 (43%) 61 (75%) 43 (53%)
b10% 78 37 (47%) 49 (63%) 62 (79%) 49 (63%)
Nuclear pleomorphism 1 17 3 (18%) .073 7 (41%) .144 9 (53%) .237 7 (41%) .246
2 92 34 (37%) 41 (45%) 71 (77%) 46 (50%)
3 83 41 (49%) 50 (60%) 64 (77%) 52 (63%)
Mitoses/10 HPFs 0-9 112 36 (32%) .010 47 (42%) .016 78 (70%) .028 56 (50%) .115
10-19 42 18 (43%) 24 (57%) 30 (71%) 23 (55%)
N19 38 24 (63%) 27 (71%) 36 (95%) 26 (68%)
Histologic grade 1 65 19 (29%) .013 25 (38%) .003 43 (66%) .035 26 (40%) .044
2 88 35 (40%) 43 (49%) 65 (74%) 53 (60%)
3 39 24 (62%) 30 (77%) 36 (92%) 26 (67%)
HER2 Negative 128 49 (38%) .382 60 (47%) .163 98 (77%) .698 70 (55%) 1.000
Positive 64 29 (45%) 38 (59%) 46 (72%) 35 (55%)
ER Negative 86 42 (49%) .074 58 (67%) b .001 63 (73%) .806 48 (56%) .889
Positive 106 36 (34%) 40 (38%) 81 (76%) 57 (54%)
PR Negative 92 43 (47%) .145 55 (60%) .046 65 (71%) .364 47 (51%) .489
Positive 100 35 (35%) 43 (43%) 79 (79%) 58 (58%)
BRCA2 Negative 87 13 (15%) b .001 36 (41%) .040 45 (52%) b .001
Positive 105 65 (62%) 62 (59%) 99 (94%)
BRCA1 Negative 48 4 (8%) b .001 24 (50%) .868
Positive 144 74 (51%) 74 (51%)
γH2AX Negative 94 27 (29%) .004
Positive 98 51 (52%)
PARP1 Negative 114 26 ± 5 .039 †
Positive 78 58 ± 17
Abbreviations: LN, lymph node; NST, invasive carcinoma of no special type; PBH, chi-square test adjusted by Benjamini-Hochberg method.
* The mean number of γH2AX-positive cells ± standard error.
† Two-sided t test.
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expression of BRCA2 predicted shorter OS (P b .001; HR, 4.284;
95% CI, 2.158-8.505) and RFS (P b .001; HR, 2.886; 95% CI,
1.692-4.925; Table 2).
Thereafter, we did further survival analysis of the subpopulation of
BCA patients who received adjuvant chemotherapy or endocrine
therapy. Among the 169 BCA patients who received systemicFigure 1. The expression and prognostic significance of PARP1, γH2A
this study. Two breast cancer cell lines (MCF7 and MDA-MB-231) w
Western blot analysis of BRCA1, BCCA2, PARP1, and γH2AX expres
PARP1, γH2AX, BRCA1, and BRCA2. (B) Immunohistochemical exp
magnification, ×400. (C) The receiver operating characteristic
immunohistochemical staining scores of PARP1, γH2AX, BRCA1, an
under the curve value representing the highest positive likelihood
indicates the cutoff point for PARP1 immunostaining, and the arrow
cells. The empty arrowhead indicates the cutoff point for BRCA1 imm
number of BRCA2 immunostaining. Cases with scores equal or gre
expression of γH2AX was considered positive when the number of γH
of BRCA1 was considered positive when the scores were equal or g
when the scores were equal or greater than 9. (D) Kaplan-Meier su
PARP1, γH2AX, and BRCA1.adjuvant chemotherapy, the expression of HER2, PR,
BRCA1 (log-rank, OS, P = .011; RFS, P = .009), BRCA2 (log-rank,
OS, P b .001; RFS, P b .001), PARP1 (log-rank, OS, P b .001; RFS,
P b .001), and γH2AX (log-rank, OS, P b .001; RFS, P b .001) was
significantly associated with shorter OS and RFS (Figure 2A). Older
age of the patients and higher tumor stage were associated with
shorter OS. Among the 166 BCA patients who received postoperativeX, and BRCA1 in 192 BCAs. (A) Validation of the antibodies used in
ere treated with camptothecin (0.1 μM) for 0.5 hour and lysed for
sion. The treatment of camptothecin increased the expressions of
ression of PARP1, γH2AX, BRCA1, and BRCA2 in BCA. Original
curve analysis for the determination of cutoff points for the
d BRCA2. The cutoff points were determined at the highest area
point for the estimation of the death of patients. The arrowhead
indicates the cutoff point for the number of γH2AX-positive tumor
unostaining, and the empty arrow indicates the cutoff point for the
ater than 13 for PARP1 expression were considered positive. The
2AX-positive cells was equal or greater than eight. The expression
reater than 7. The expression of BRCA2 was considered positive
rvival analysis for the OS and RFS according to the expression of
Table 2. Univariate Cox Proportional Hazards Regression Analysis for OS and RFS in BCA Patients
Characteristics No. OS RFS
HR (95% CI) P HR (95% CI) P
Age, years, ≥50 (vs b50) 61/192 2.808 (1.652-4.773) b .001 1.713 (1.072-2.739) .025
TNM stage
I 35/192 1 .002 1 .045
II 124/192 2.691 (0.957-7.573) .061 1.860 (0.879-3.937) .105
III and IV 33/192 5.915 (1.974-17.719) .001 2.877 (1.241-6.670) .014
Histologic grade
1 65/192 1 b .001 1 .046
2 88/192 1.482 (0.737-2.979) .269 1.182 (0.674-2.074) .56
3 39/192 3.527 (1.723-7.222) b .001 2.072 (1.123-3.824) .02
HER2, positive (vs negative) 64/192 1.836 (1.079-3.123) .025 1.608 (1.006-2.569) .047
ER, negative (vs positive) 86/192 1.813 (1.063-3.091) .029 1.475 (0.929-2.343) .099
PR, negative (vs positive) 92/192 2.125 (1.233-3.662) .007 2.066 (1.286-3.320) .003
BRCA2, positive (vs negative) 105/192 4.284 (2.158-8.505) b .001 2.886 (1.692-4.925) b .001
BRCA1, positive (vs negative) 144/192 2.965 (1.269-6.926) .012 2.392 (1.226-4.667) .011
PARP1, positive (vs negative) 98/192 5.778 (3.143-10.623) b .001 3.039 (1.889-4.888) b .001
γH2AX, positive (vs negative) 78/192 4.725 (2.439-9.154) b .001 3.706 (2.172-6.325) b .001
CSbbph
Low 68/192 1 b .001 1 b .001
Intermediate 81/192 4.535 (1.556-13.212) .006 2.789 (1.367-5.689) .005
High 43/192 18.805 (6.608-53.519) b .001 7.975 (3.894-16.336) b .001
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HER2, PR, BRCA1 (log-rank, OS, P = .009; RFS, P = .009),
BRCA2 (log-rank, OS, P b .001; RFS, P b .001), PARP1 (log-rank,
OS, P b .001; RFS, P b .001), and γH2AX (log-rank, OS, P b .001;
RFS, P b .001) were significantly associated with both OS and RFS
(Figure 2B).
Among the 33 triple-negative BCAs (HER2−/ER−/PR−), PARP1
expression predicted shorter OS (P = .017; HR, 12.256; 95% CI,
1.564-96.035) and RFS (P = .046; HR, 3.227; 95% CI,
1.023-10.172). γH2AX positivity was significantly associated with
shorter OS (log-rank, P = .002) and RFS (P = .015; HR, 6.389; 95%
CI, 1.433-28.486). BRCA2 expression was significantly associated
with shorter OS (P = .018; HR, 6.429; 95% CI, 1.382-29.909).
However, the expression of BRCA1 was not associated with the
prognosis of the triple-negative BCA (Figure 2C ).
Furthermore, we evaluated the prognostic effect of the combined
expression of PARP1, γH2AX, BRCA1, and BRCA2. When we
focused our analysis on the expressional status of BRCA1 and
BRCA2, PARP1 expression predicted shorter OS and RFS in the
BRCA1−, BRCA1+, BRCA2−, and BRCA2+ subgroups (Table 3).
PARP1 expression also predicted shorter OS in the both γH2AX-
and γH2AX+ subgroups (Table 3). γH2AX positivity was associated
with shorter OS and RFS in the BRCA1+, BRCA2+, and PARP1+
subgroups (Table 3). Because the expressions of PARP1, γH2AX,
BRCA1, and BRCA2 were closely related (Table 1), the combined
score for the immunohistochemical expression of BRCA1, BRCA2,
PARP1, and γH2AX (CSbbph) was established with the sum of
positivity of BRCA1, BRCA2, PARP1, and γH2AX (negative, 0;
positive, 1; i.e., BRCA1+/BRCA2+/PARP1+/γH2AX+ = 1 + 1 + 1 +
1 = CSbbph 4). The CSbbph ranged from zero (BRCA1−/BRCA2−/
PARP1−/γH2AX-) to four (BRCA1+/BRCA2+/PARP1+/γH2AX+).
Thereafter, CSbbph scores were grouped as CSbbph-low (CSbbph
0-1), CSbbph-intermediate (CSbbph 2-3), and CSbbph-high
(CSbbph 4). Among the 192 general cases of BCA, CSbbph was
significantly associated with OS (P b .001) and RFS (P b .001;
Figure 3 and Table 2). The OS rates at 10 years (10y-OS) of the
CSbbph-low, the CSbbph-intermediate, and the CSbbph-high
subgroups were 95%, 79%, and 35%, respectively (Figure 3).The Expression of PARP1, γH2AX, and BRCA2, and BRCA1/
BRCA2/PARP1/γH2AX Expression Pattern Is the Independent
Unfavorable Prognostic Predictor of BCA Patients
The clinicopathologic factors significantly associated with OS and/
or RFS by univariate analysis were included in the multivariate
analysis (Table 4). Among the 192 cases of BCA, tumor stage, PARP1
expression, γH2AX positivity, and BRCA2 expression were
independent prognostic indicators of both OS and RFS. The
expression of PARP1 predicted a 3.648-fold (95% CI,
1.885-7.059; P b .001) greater risk of death and a 1.958-fold
(95% CI, 1.146-3.347; P = .014) greater risk of shorter RFS. γH2AX
positivity predicted a 3.564-fold (95% CI, 1.793-7.085; P b .001)
greater risk of death and a 3.077-fold (95% CI, 1.767-5.357; P b
.001) greater risk of shorter RFS. The expression of BRCA2 predicted
a 2.098-fold (95% CI, 1.004-4.382; P = .049) greater risk of death
and a 1.868-fold (95% CI, 1.025-3.407; P = .041) greater risk of
shorter RFS (Table 4). The age of the patient (P = .032) was an
independent prognostic indicator of OS, and loss of PR expression
predicted shorter RFS (P = .021). When multivariate analysis was
performed with the inclusion of CSbbph instead of the individual
expression of PARP1, γH2AX, BRCA1, or BRCA2, CSbbph
expression was significantly associated with OS (P b .001) and RFS
(P b .001; Table 4).
Among the subpopulation of patients who received chemotherapy
or endocrine therapy, tumor stage, the expression of PARP1 and
γH2AX, and CSbbph were independent prognostic predictors of OS
and RFS. All P values were less than .05.
Discussion
During the treatment of human malignant tumors with genotoxic
agents, the expression of PARP1 and γH2AX is observed in tumor
cells and is thought to promote the survival of tumor cells by repairing
DNA damage [38]. In agreement with these reports, our result
demonstrated the expression of PARP1, γH2AX, and BRCA2 to be
independent indicators of poor prognosis of BCA, especially in the
subpopulation of BCA patients who received adjuvant chemotherapy.
In line with our results, it has been reported that the expression of
PARP1 or γH2AX in human malignant tumors is associated with
tumor progression and poor survival of patients with human
Figure 2. Kaplan-Meier survival analysis according to the expression of PARP1, γH2AX, BRCA1, and BRCA2 in the subpopulations of
BCAs. (A) OS and RFS in 169 BCA patients who received adjuvant chemotherapy. (B) OS and RFS in 166 BCA patients who received
postoperative endocrine therapy. (C) OS and RFS in 33 triple-negative (HER2−/ER−/PR−) BCA patients.
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Table 3. Univariate Cox Proportional Hazards Regression Analysis for Survival in Various Subgroups of BCA according to the Expression of BRCA1, BRCA2, PARP1, and γH2AX
IHC Subgroup No. PARP1, Positive (vs Negative) γH2AX, Positive (vs Negative) BRCA2, Positive (vs Negative) BRCA1, Positive (vs Negative)
OS RFS OS RFS OS RFS OS RFS
BRCA1 Negative 48 HR (95% CI) 7.581
(1.364-42.120)
5.890
(1.516-22.875)
5.393
(0.629-46.224)
2.694
(0.696-10.426)
4.710
(0.853-25.996)
1.986
(0.421-9.361)
P .021 .010 .124 .151 .075 .386
Positive 144 HR (95% CI) 5.106
(2.539-10.266)
2.422
(1.429-4.104)
4.775
(2.381-9.577)
3.995
(2.229-7.159)
3.64
(1.548-8.557)
2.619
(1.330-5.156)
P b .001 .001 b .001 b .001 .003 .005
BRCA2 Negative 87 HR (95% CI) 6.456
(1.866-22.328)
3.237
(1.214-8.633)
3.422
(0.884-13.241)
2.431
(0.942-6.275)
1.447
(0.407-5.144)
1.289
(0.509-3.268)
P .003 .019 .075 .066 .568 .592
Positive 105 HR (95% CI) 3.563
(1.710-7.426)
2.026
(1.128-3.639)
4.465
(2.076-9.603)
3.949
(2.032-7.676)
1.156
(0.280-4.774)
1.615
(0.393-6.633)
P b .001 .018 b .001 b .001 .842 .506
γH2AX Negative 94 HR (95% CI) 3.409
(1.033-11.248)
2.104
(0.830-5.333)
3.155
(0.837-11.894)
1.891
(0.733-4.880)
3.536
(0.452-27.687)
1.931
(0.559-6.671)
P .044 .117 .090 .188 .229 .298
Positive 98 HR (95% CI) 5.353
(2.565-11.172)
2.706
(1.530-4.784)
3.915
(1.743-8.795)
2.892
(1.488-5.622)
2.967
(1.169-7.531)
2.733
(1.233-6.057)
P b .001 b .001 b .001 .002 .022 .013
PARP1 Negative 114 HR (95% CI) 2.632
(0.882-7.858)
2.861
(1.320-6.201)
3.115
(1.042-9.309)
2.432
(1.150-5.146)
1.465
(0.457-4.692)
1.931
(0.820-4.547)
P .083 .008 .042 .020 .520 .132
Positive 78 HR (95% CI) 4.507
(1.891-10.741)
3.577
(1.654-7.733)
1.75
(0.686-4.469)
1.472
(0.622-3.485)
1.101
(0.265-4.562)
0.825
(0.255-2.666)
P b .001 .001 .242 .379 .895 .747
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sistance, and c-Myc–bridging integrator 1 (BIN1)–PARP1 signaling
pathways induce resistance to cisplatin; overexpression of c-MycFigure 3. Prognostic significance of the combined expression pattern
survival analysis for OS (A) and RFS (B) between the subgroups classi
positivity of BRCA1, BRCA2, PARP1, and γH2AX (negative, 0; positiv
CSbbph-intermediate (CSbbph 2-3), and CSbbph-high (CSbbph 4); 10suppresses BIN1 and consequently releases PARP1, resulting in an
induction of chemoresistance [39]. In addition, the inhibition of
PARP1 activity induced BIN1-mediated suppression of c-Myc [39].of PARP1, γH2AX, BRCA1, and BRCA2 in 192 BCAs. Kaplan-Meier
fied according to CSbbph. CSbbph was established with the sum of
e, 1). CSbbph scores were grouped as CSbbph-low (CSbbph 0-1),
y-RFS, RFS rate at 10years.
Table 4. Multivariate Cox Proportional Hazards Regression Analysis for OS and RFS in BCA
Patients
Characteristics OS RFS
HR (95% CI) P HR (95% CI) P
Age, years, ≥50 (vs b50) 1.830 (1.052-3.182) .032
TNM stage
I 1 .001 1 .011
II 2.641 (0.924-7.544) .070 2.121 (0.996-4.516) .051
III and IV 6.676 (2.133-20.899) .001 3.626 (1.545-8.512) .003
PR, negative (vs positive) 1.733 (0.990-3.032) .054 1.773 (1.091-2.881) .021
BRCA2, positive (vs negative) 2.098 (1.004-4.382) .049 1.868 (1.025-3.407) .041
PARP1, positive (vs negative) 3.648 (1.885-7.059) b .001 1.958 (1.146-3.347) .014
γH2AX, positive (vs negative) 3.564 (1.793-7.085) b .001 3.077 (1.767-5.357) b .001
CSbbph †
Low 1 b .001 1 b .001
Intermediate 3.955 (1.337-11.702) .013 2.979 (1.457-6.089) .003
High 17.155 (5.914-49.762) b .001 7.958 (3.866-16.380) b .001
* The variables included in the multivariate analysis were age, TNM stage, histologic grade, and the
expression of HER2, ER, PR, BRCA1, BRCA2, PARP1, and γH2AX.
† The variables included in the multivariate analysis were age, TNM stage, histologic grade, the expression
of HER2, ER, and PR, and CSbbph.
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prostate cancer stem–like cells was associated with increased
expression of γH2AX that arrests cell cycle in the G2/M phase
[40]. Therefore, inhibiting PARP- and/or γH2AX-mediated DNA
repair responses during chemotherapy could be a good stratagem for
the treatment of subgroup of BCA patients with tumors expressing
PARP1 and γH2AX.
When there is no γH2AX-BRCA1/2–related repair of DSB,
PARP1 inhibitors block PARP1-mediated repair of the single-stand
breaks, resulting in death of tumor cells from unrepairable DSB.
Therefore, cancers with BRCA1/2 mutations could be susceptible to
treatments with PARP1 inhibitors [3,13,25], and a recent report has
shown that the PARP1 inhibitor, olaparib, could be employed in the
treatment of BRCA1/2-deficient BCA [13]. Thus, the prognostic
implications of PARP1 expression could vary according the BRCA1
expressional status. However, the expression of PARP1 was a poor
prognostic indicator in the general population of BCA [5] and lymph
node negative stage II BCA [41]. Our result also showed that the
expression of PARP1 is associated with poor prognosis in the both
BRCA1− and BRCA1+ subgroups. Moreover, the patients with
BRCA1+/BRCA2+/PARP1+/γH2AX+ BCA showed the shortest
survival with 35%OS at 10 years. These results suggest the possibility
that PARP1 inhibitors might be useful for the treatment of BCA
patients regardless of the expression status of BRCA1. Although some
reports have shown that PARP inhibitors do not show promising
results outside of BRCA-associated BCA patients [1,26], the survival
benefits of veliparib, a PARP inhibitor, plus temozolomide
chemotherapy in metastatic BCAs have been reported [26]. Olaparib,
an oral PARP inhibitor, also demonstrated therapeutic effectiveness in
the ovarian carcinoma without BRCA1/2 mutation [27]. In addition,
the usefulness of PARP inhibitors has been suggested in RECQL4/
hormone receptor–deficient tumors and that was independent of
BRCA-ness [42]. In the BCA subgroup receiving adjuvant
chemotherapy in our study, the expression of PARP1 and γH2AX
was also significantly associated with shorter OS and RFS. Moreover,
recently, it has been reported that two kinds of PARP inhibitors,
olaparib and rucaparib, potentiated antitumor activity of trastuzumab
in HER2-overexpressing BCA [12]. However, our study has the
limitation in that we did not investigate the mutation of BRCA1.
Thus, it is not clear whether the immunohistochemical loss ofBRCA1 and/or BRCA2 expression could be useful in the estimation
of the mutation of the BRCA1/2 gene. In addition, it has been
reported that the expression of PARP1 is upregulated in triple-
negative BCA [4]. However, in our study, the expression of PARP1
(P = .162) or γH2AX (P = .227) was not significantly different
between triple-negative BCA and non–triple-negative BCA. In
contrast, as shown in Figure 2C, the expression of PARP1 and
γH2AX correlated with shorter survival of triple-negative BCA
patients. However, further study is needed to clarify whether the
expression of PARP1 and γH2AX really affects the survival of
triple-negative BCA patients because of the relatively low number of
triple-negative cases in this study. Nevertheless, a recent report
showed a reliable correlation between BRCA1 immunostaining and
BRCA1 mutation in ovarian carcinomas. Negative or weak staining
in less than 10% of tumor cells for BRCA1immunostaining was
predictive of BRCA1 mutation [28]. That criterion was similar to the
cutoff point for BRCA1 immunostaining used in our study. If 10% of
tumor cells stained weakly in two TMA cores, they were scored as six
and included in the BRCA1− subgroup. Thereby, on the basis of our
cutoff value for the BRCA1 immunostaining, our findings suggest
that the prognostic value of PARP1 expression for BCA patients may
also be predictive for BCA patients, who have not had a molecular
event in BRCA1.
Concerning the prognostic impact of BRCA1 and BRCA2
expression status, our results have shown that the loss of
immunohistochemical expression of BRCA1 and BRCA2 is
associated with favorable prognosis. However, the prognostic impact
of BRCA1/2 expression status has been debated in the literature.
Earlier reports showed that BRCA1/2-related BCA had a favorable
prognosis [43]; however, poor prognosis in BRCA1/2-mutated BCA
patients has also been reported [44] and there were no prognostic
differences between BRCA1-related BCA and BRCA1-unrelated
BCA in other reports [45,46]. The 10-year survival rates for carriers of
the BRCA1 mutation and non-carriers were reported as 80.9% and
82.2%, respectively [46]. However, in our study, immunohisto-
chemical expression of both BRCA1 and BRCA2 was significantly
associated with shorter OS and RFS. The 10-year OS rates were 90%,
91%, 70%, and 62% in the BRCA1−, BRCA2−, BRCA1+, and
BRCA2+ subgroups, respectively. Similarly, a recent report has shown
that immunohistochemical expression of nuclear BRCA1 is associated
with poor survival of BCA [37] and ovarian serous carcinomas [47].
However, when considering the role of BRCA1/2 as a potent tumor
suppressor, the poor prognosis in BRCA1/2-expressing BCA patients
is paradoxical. This finding might be related with the fact that
BRCA1/2-defective cells are more sensitive to chemotherapeutic
agents. In ovarian carcinomas, BRCA1/2 defectiveness was related
with platinum resistance [48–50]. In our study, nuclear expression of
BRCA1 and BRCA2 was associated with shorter survival in the
subgroup of BCA patients who received adjuvant chemotherapy.
Therefore, it is suggested that BRCA-ness is associated with
chemoresistance. In addition to the nuclear expression of BRCA1,
it has been suggested that cytoplasmic expression of BRCA1 is
representative of mutant BRCA1 [51]. Therefore, we separately
analyzed the cytoplasmic expression of BRCA1/2 and expected that
the result might be opposite to the result from the nuclear expression
of BRCA1. However, cytoplasmic expression of BRCA1 and BRCA2
was also significantly associated with shorter OS (log-rank, BRCA1,
P b .001; BRCA2, P b .001) and RFS (log-rank, BRCA1, P b .001;
BRCA2, P b .001; Figure S1). These findings suggest that generalized
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BCA and/or response to the chemotherapy, but further studies
are needed to clarify the role of BRCA1/2 according to its
intracellular localization.
Another interesting result of our study is that the combined
expression patterns of BRCA1, BRCA2, PARP1 and γH2AX were
very predictive of the survival of BCA patients. When three or more
markers are included in the negative group (CSbbph-low), the
10y-OS was 95% and that represented 35% (68/192) of BCA
patients. The survival rate gradually decreased with the increase of the
CSbbph score. The 10y-OS of the CSbbph-intermediate subgroups
was 79% and that was only 35% in the CSbbph-high subgroup. This
poorest survival group represented 22% (43/192) of BCA patients.
Therefore, our results suggest that evaluating the immunohistochem-
ical expression patterns of BRCA1, BRCA2, PARP1, and γH2AX is
very helpful for the prediction of the prognosis of BCA patients. In
addition, the poor prognostic BCA group expressing DDR molecules
could potentially benefit from treatments with drugs such as PARP1
inhibitors, which target DNA damage–related molecules.
In conclusion, this study has shown that the expression of DDR
signaling molecules is closely correlated with and helpful for the
prediction of the prognosis of BCA patients. Especially, when these
DDR signaling molecules are expressed simultaneously, as in the
CSbbph-high subgroup in our study, the patients showed very short
survival. To the best of our knowledge, this is the first report
describing the possible prognostic role of the co-expression of
BRCA1, BRCA2, PARP1, and γH2AX in breast cancer patients.
Moreover, when we consider that the immunohistochemical
evaluation of biopsies is easy and practical, our results suggest that
immunohistochemical evaluation of BRCA1, BRCA2, PARP1, and
γH2AX could be helpful for the prediction of the prognosis of BCA
and for the selection of BCA patients who could potentially be the
subject of anti-PARP1 therapy during genotoxic agent-based
adjuvant chemotherapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.04.004.
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